SOURCE: Crucell N.V.

November 06, 2007 08:09 ET

Crucell to Release Q3 2007 Earnings on Tuesday, November 13, 2007

LEIDEN, NETHERLANDS--(Marketwire - November 6, 2007) -



Leiden, The Netherlands, 6 November 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that it will release its financial results for the third quarter of 2007 on Tuesday, November 13, 2007 at 08:00 Central European Time (CET).

At 14:00 Central European Time, Crucell will conduct a conference call open to all, which will also be webcast. To participate in the conference call, please call one of the following numbers 10 minutes prior to commencement:

                     1 888 457 4228 for the US;
                    0800-358 0886 for the UK; and
                  0800-265 8546 for the Netherlands

Following a presentation of the results you will be able to ask questions during a question and answer session.

The live audio webcast can be accessed via the homepage of Crucell's website at www.crucell.com and will be archived and available for replay following the event.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad pipeline, with several products based on its unique PER.C6® production technology in development. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20- F, as filed with the U.S. Securities and Exchange Commission on June 13, 2007, and the section entitled "Risk Factors". The Company prepares its financial statements under International Financial Reporting Standards (IFRS) with reconciliation to the generally accepted accounting principles in the United States (US GAAP). For further information please contact:

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information


  • Crucell Media:
    Barbara Mulder
    Director Corporate Communications
    Tel: 31-(0)71-519 7346
    Email Contact

    Crucell Investors/Analysts:
    Oya Yavuz
    Director Investor Relations
    Tel. +31-(0)71-519 7064
    Email Contact